| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD004571.PUB2 |
| P698 | PubMed publication ID | 18843663 |
| P2093 | author name string | Rosaline Quinlivan | |
| Margaret F Phillips | |||
| P2860 | cites work | Cochrane Database of Systematic Reviews | Q15750361 |
| The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle | Q24297845 | ||
| Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study | Q78175272 | ||
| Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation | Q78616932 | ||
| Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy | Q79489519 | ||
| Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy | Q80201682 | ||
| Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery | Q80357107 | ||
| Influence of calcium channel blocker drugs in neuromuscular transmission | Q80650164 | ||
| Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix | Q28296676 | ||
| Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex | Q28346540 | ||
| Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers | Q28593090 | ||
| Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals | Q30050310 | ||
| Delayed diagnosis of Duchenne muscular dystrophy | Q34059115 | ||
| Allocation concealment in randomised trials: defending against deciphering | Q34116070 | ||
| Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibers detected with Ca2+-activated K+ channels. | Q35700706 | ||
| Dystrophin protects the sarcolemma from stresses developed during muscle contraction | Q36259954 | ||
| A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel | Q36323554 | ||
| Increased calcium influx in dystrophic muscle | Q36530501 | ||
| Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies | Q39486051 | ||
| Stages in fibre breakdown in Duchenne muscular dystrophy. An electron-microscopic study | Q39918719 | ||
| Reduction in intracellular calcium levels inhibits myoblast differentiation | Q40728039 | ||
| Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers | Q41882302 | ||
| Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin | Q44177784 | ||
| Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface | Q44350613 | ||
| Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine | Q44532758 | ||
| Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy | Q46627068 | ||
| The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy | Q46943097 | ||
| Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial | Q48752237 | ||
| Experimental mouse muscle damage: the importance of external calcium. | Q51847995 | ||
| Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. | Q53252919 | ||
| Regulation of membrane-mediated chronic muscle degeneration in dystrophic hamsters by calcium-channel blockers: diltiazem, nifedipine and verapamil. | Q54330523 | ||
| Effects of Long-term Treatment with Verapamil on Left Ventricular Function and Myocardial Blood Flow in Patients with Dilated Cardiomyopathy Without Overt Heart Failure | Q61650833 | ||
| Acute respiratory failure following intravenous verapamil in Duchenne's muscular dystrophy | Q67271824 | ||
| Effect of dantrolene in Duchenne muscular dystrophy | Q67916581 | ||
| Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy | Q68131101 | ||
| Neuromuscular block by verapamil and diltiazem and inhibition of acetylcholine release | Q68483994 | ||
| Effect of chronic administration of verapamil in Duchenne muscular dystrophy | Q68494185 | ||
| A trial of flunarizine in the treatment of Duchenne muscular dystrophy | Q68879856 | ||
| Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine | Q68945618 | ||
| A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy | Q69050836 | ||
| Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin in Duchenne muscular dystrophy | Q69550785 | ||
| Clinical trial in Duchenne dystrophy. I. The design of the protocol | Q70155092 | ||
| Selective potentiation of subtetanic and tetanic contractions by the calcium-channel antagonist nifedipine in the rat diaphragm preparation | Q70198796 | ||
| Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy | Q70410817 | ||
| In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy | Q71352955 | ||
| Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group | Q71545362 | ||
| Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch | Q72102757 | ||
| Verapamil in Duchenne muscular dystrophy | Q72520324 | ||
| Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury | Q74101706 | ||
| Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine | Q74596197 | ||
| Muscular degeneration in the absence of dystrophin is a calcium-dependent process | Q77129602 | ||
| P921 | main subject | Duchenne muscular dystrophy | Q1648484 |
| P577 | publication date | 2008-10-08 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Calcium antagonists for Duchenne muscular dystrophy |
| Q35649642 | Aquapuncture Using Stem Cell Therapy to Treat Mdx Mice |
| Q36657133 | Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo |
| Q91926020 | Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of Duchenne muscular dystrophy |
| Q55280427 | Diltiazem improves contractile properties of skeletal muscle in dysferlin-deficient BLAJ mice, but does not reduce contraction-induced muscle damage. |
| Q38257886 | Dysregulation of calcium homeostasis in muscular dystrophies. |
| Q33608478 | Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies |
| Q30574663 | Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery. |
| Q37414983 | Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR tagging |
| Q33991780 | Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy |
| Q36309327 | Focal but reversible diastolic sheet dysfunction reflects regional calcium mishandling in dystrophic mdx mouse hearts. |
| Q28085320 | Genetic evidence in the mouse solidifies the calcium hypothesis of myofiber death in muscular dystrophy |
| Q34059173 | Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy |
| Q57456679 | Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy |
| Q35069506 | Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice |
| Q34490590 | Orai1 mediates exacerbated Ca(2+) entry in dystrophic skeletal muscle |
| Q34152280 | Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials |
Search more.